Gilead Sciences (GILD) Stock Forecast & Price Target

Gilead Sciences is experiencing robust growth, reflected in increased sales driven by higher demand and considerable market share gains, particularly in its HIV portfolio, where Biktarvy commands 52% of the U.S. market. The company has raised its growth guidance for its HIV segment to 5% year-over-year, indicating confidence in ongoing performance despite potential headwinds in Medicare Part D. Additionally, Gilead's expansion efforts in the oncology market, exemplified by the successful launch of Livdelzi, which generated $105 million in its first full year, further enhance the positive outlook for the company's financial trajectory.

Gilead Sciences faces a challenging financial outlook, highlighted by a significant decline in its key product revenues, such as Veklury, which experienced a 60% year-over-year decrease, resulting in revenue of only $277 million, well below expectations. Additionally, the company anticipates a roughly 10% year-over-year revenue drop for its cell therapy segment in 2025, further compounded by competitive headwinds impacting sales across the board. The performance of Trodelvy also reflects weakness, with a slight quarterly sales decline to $357 million, indicating struggles in maintaining growth momentum amid an increasingly competitive landscape.